



**PHARMACY AND THERAPEUTICS COMMITTEE
ACA/Exchange MEETING MINUTES
August 27, 2026**

Attendance:

Microsoft Teams Meeting

Rojin Baniyadi, Pharmacy Resident; Kelly Bartolone, Staff/Clinical Pharmacist; Gary Bledsoe, Staff/Clinical Pharmacist; Connie Chan, Staff/Clinical Pharmacist; Dr. Edgar Chou, Jefferson Health; Dr. Neal Demp, Community Behavior Health; Danielle Dolores, Director Pharmacy Services; Dr. George E. Downs, Dean Emeritus and Professor, St. Joseph's University; Leah Finken, Clinical Programs Pharmacist; Sharon Ford, Staff/Clinical Pharmacist; Paul Goebel, Assistant Director Pharmacy, Jefferson Enterprise; Lauren Grantz, Administrator Outpatient Pharmacy Services, Jefferson Enterprise; Yelena Hedrick, Staff/Clinical Pharmacist; Gia Ho, Pharmacy Resident; Samantha Jackson, Formulary Pharmacist; Ruth John, Staff/Clinical Pharmacist; Lawrence Jones, Retired Executive Director, Pennsylvania Society of Health-System Pharmacists (PSHP); Kaylei Koerwitz, Manager Pharmacy Operations and Clinical Programs; Dr. Tania Kolev, Medical Director; Brandi Mahler, Supervisor Pharmacy Technicians; Hannah McCaffrey, Manager Pharmacy Regulations & Implementations; Derek McFerran, Vice President, Pharmacy Operations; Michele McKenna, Staff/Clinical Pharmacist; Janvi Morker, Pharmacy Student Intern; Lisa Murray, Staff/Clinical Pharmacist; Saad Nayyer, Pharmacy Student Intern; Jennifer Nguyen, Pharmacy Student Intern; Claudia Pinketti, Staff/Clinical Pharmacist; Ryan Prager, Staff/Clinical Pharmacist; Maryana Prokopets, Staff/Clinical Pharmacist; Kateryna Puia, Clinical Programs Pharmacist; Heather Scheckner, Clinical Pharmacist, Jefferson Health; Mike Smikovec, Staff/Clinical Pharmacist; Robert Spencer, Staff/Clinical Pharmacist; Shelley Staffa, Clinical Pharmacist; Justin Steffan, Staff/Clinical Pharmacist; Michelle Tran, Pharmacy Resident; Fallan Vaisberg, Formulary Pharmacist; Reena Varghese, Staff/Clinical Pharmacist; Jeanine Zubrzycki, Staff/Clinical Pharmacist

Excused:

Dr. Paul Aitken, Medical Director; Jerry Crawford, Staff/Clinical Pharmacist; Kristen DeSorte, Staff/Clinical Pharmacist; Dr. Demian Elder, Medical Director; Hailey Fry, Centennial Pharmacy; Dr. Merleen Harris-Williams, Medical Director; Jessica Hoang-Le, Staff/Clinical Pharmacist; Sheenu Joseph, Staff/Clinical Pharmacist; Sanjiv Raj, Associate VP Customer Engagement; Sara Sadiq, Staff/Clinical Pharmacist; Julie Samuel, Clinical Programs Pharmacist; Dr. Chris Squillaro, Medical Director, Magellan Behavioral Health; Tara Swartz, Staff/Clinical Pharmacist

Minutes taken by: Joana Iverson

I. Administrative Update

TOPIC	DISCUSSION	ACTIONS	RESPONSIBLE PARTY	RESOLVED/ PENDING
Minutes Review/Approval	D. Dolores presented the minutes from the May 2026 meeting to the Committee for review.	The Committee approved the minutes from our last meeting as presented.	D. Dolores	Resolved

TOPIC	DISCUSSION	ACTIONS	RESPONSIBLE PARTY	RESOLVED/PENDING
<i>NCQA Updates</i>	<i>D. Dolores provided an update</i> <i>NCQA Survey – June 2026 Exchange HMO</i> <i>NCQA UM 11DE – Information Integrity Audit</i>	<i>Informational</i>	<i>D. Dolores</i>	

II. 2027 Formulary Updates

TOPIC	DISCUSSION	ACTIONS	RESPONSIBLE PARTY	RESOLVED/PENDING
<i>Tier Changes (PID Objection Review)</i>	<i>The Committee reviewed the Tier Changes. The Committee approved as presented.</i> <i>Abirtega - Move to T3</i> <i>Xdemvy - Move to T4</i>	<i>The Committee approved as presented.</i>	<i>J. Zubrzycki</i>	<i>Resolved</i>
<i>2027 Formulary Removals</i>	<i>The Committee reviewed the 2027 Formulary Removals.</i> <i>Kisqali Femara (400 mg dose) 200 & 2.5 mg tab thpk</i> <i>Kisqali Femara (600 mg dose) 200 & 2.5 mg tab thpk</i>	<i>The Committee approved as presented.</i>	<i>J. Zubrzycki</i>	<i>Resolved</i>
<i>2026 and 2027 Formulary Additions</i>	<i>The Committee reviewed the 2026 and 2027 Formulary Additions.</i> <i>Bosutinib - T5, PA</i> <i>Brivaracetam - T4, ST</i> <i>Kymbee suspension - T4, PA</i> <i>Macitentan - T5, PA</i> <i>Sitagliptan - T3</i> <i>Sitagliptan-Metformin - T3</i> <i>Tacrolimus ER - T4</i> <i>Tofacitinib - T5, PA</i> <i>Tofacitinib ER - T5, PA</i> <i>Yulithira - T3</i>	<i>The Committee approved as presented.</i>	<i>J. Zubrzycki</i>	<i>Resolved</i>

III. 2027 Prior Authorization Review/Update

<i>2027 Prior Authorization Criteria Review</i>	<i>The Committee reviewed the 2027 Prior Authorization Criteria. The Committee approved as presented.</i> <i>Off-label use</i> <i>Actimmune</i> <i>Acute Seizure Agents NSO</i> <i>Adalimumab</i> <i>Adempas</i>	<i>The Committee approved as presented.</i>	<i>J. Zubrzycki</i> <i>H. McCaffrey</i> <i>F. Vaisberg</i> <i>S. Jackson</i> <i>S. Staffa</i> <i>G. Bledsoe</i> <i>J. Steffan</i>	<i>Resolved</i>
---	--	---	---	-----------------

	• <i>Alpha-1 Proteinase Inhibitors</i> • <i>Apomorphine</i> • <i>Arcalyst</i> • <i>Austedo</i> • <i>Carglumic Acid</i> • <i>CGRP Antagonists</i> • <i>Corticotropin Gel</i> • <i>Cystaran</i> • <i>Deferasirox</i> • <i>Deferiprone</i> • <i>Denosumab (Xgeva and biosimilars)</i> • <i>Diacomit NSO</i> • <i>Dihydroergotamine Nasal</i> • <i>Doptelet</i> • <i>Dupixent</i> • <i>Eltrombopag</i> • <i>Empaveli</i> • <i>Enbrel</i> • <i>Endothelin Receptor Antagonists</i> • <i>Epidiolex NSO</i> • <i>Eucrisa</i> • <i>Filgrastim Agents</i> • <i>Gattex</i> • <i>Hemophilia Agents</i> • <i>Icatibant</i> • <i>Ingrezza</i> • <i>Journavx</i> • <i>Kerendia</i> • <i>Kesimpta</i> • <i>Mavyret</i> • <i>Myalept</i> • <i>Nucala</i> • <i>Ofev</i> • <i>Opipza Oral Film</i> • <i>Phosphodiesterase-5 Inhibitors PDE5I</i> • <i>Pirfenidone</i> • <i>Pulmozyme</i> • <i>Regranex</i> • <i>Revcovi</i> • <i>Rufinamide NSO</i> • <i>Skyrizi</i> • <i>Sodium Oxybate – Xyrem/Xywav</i>		<i>M. Prokopets</i> <i>S. Ford</i> <i>R. Spencer</i> <i>R. John</i> <i>Y. Hedrick</i>	
--	---	--	---	--

	• <i>Sodium Phenylbutyrate</i> • <i>Tadalafil for BPH</i> • <i>Tarpeyo</i> • <i>Teriparatide</i> • <i>Testosterone Replacement Therapy</i> • <i>Tetrabenazine</i> • <i>Topical retinoids</i> • <i>Uptravi</i> • <i>Ventavis</i> • <i>Xdemvy</i> • <i>Xermelo</i> • <i>Xifaxan</i> • <i>Xolair</i> <i>Prior authorization criteria will continue for the 2027 benefit year.</i>			
--	---	--	--	--

IV. New Drug Review	<i>(Presented in New Drug Review for Medicaid.)</i> <i>The following new products were reviewed and will be kept as non-formulary:</i> • <i>Gwyn Lo (ethinyl estradiol and norelgestromin) Transdermal System</i> • <i>Garzulys (insulin aspart-fsan) Injection</i> • <i>Lytenava (bevacizumab-vikg) Intravitreal Injection - formerly ONS-5010</i> • <i>Simtriyo (centanafadine) Extended-Release Capsules</i> • <i>Tylenol with Naproxen (acetaminophen and naproxen sodium) Tablets</i> • <i>Jideytro (zidesamtinib) Tablets</i> • <i>Lipfendra (enlicitide) Tablets</i> • <i>Revtorpyk (gedatolisib) Lyophilized Powder for Injection</i> • <i>Sarclisa Escena (isatuximab-irfc) Subcutaneous Injection</i> • <i>Trutakna (atacicept-vymj) Injection</i> • <i>Tregzi (allogeneic regulatory T cell immunotherapy with HSPC and T cells-vldq) - formerly Orca-T</i> • <i>Lumvoa (veligrotug-vvze) Injection</i> • <i>Utebzi (tebipenem pivoxil) Tablets</i> • <i>Ambelvist (gadoquatrane) Injection</i>	<i>The Committee approved as presented and recommended.</i>	<i>R. Baniasadi</i>	<i>Resolved</i>
----------------------------	---	---	---------------------	-----------------

	• <i>Ranluspec (ranibizumab-hkdz) Intravitreal Injection</i> • <i>Xocova (ensitrelvir) Tablets</i> • <i>Zaynich (cefepime and zidebactam) Powder for Injection</i> • <i>Cavhanza (nilotinib) Orally Disintegrating Tablets</i> • <i>Cypsedo (cipepofol) Injection</i> • <i>Decnupaz (pivekimab sunirine-pvzy) Lyophilized Cake for Injection</i> • <i>Hepcludex (bulevirtide-gmod) Lyophilized Powder for Injection</i> • <i>Differin Epiduo Acne Gel (adapalene and benzoyl peroxide) Topical Gel</i> • <i>Baxfendy (baxdrostat) Tablets</i> • <i>Immgolis (golimumab-sldi) Injection</i> • <i>Trimbow (beclomethasone dipropionate, formoterol fumarate and glycopyrrolate) Inhalation Aerosol</i> • <i>Beqalzi (sonrotoclax) Tablets</i> • <i>Ennumo (pegfilgrastim-pccg) Injection</i> • <i>Veppanu (vepdegestrant) Tablets</i> • <i>Langlara (insulin glargine-aldy) Injection</i> • <i>Otarmeni (lunsotogene parvec-cwha) Suspension for Intracochlear Infusion</i> • <i>Idvynso (doravirine and islatravir) Tablets</i>			
--	--	--	--	--

V. Adjournment

There being no further business to discuss, the meeting was adjourned. Next meeting is to be held October 2026.



9/2/2026

Danielle Dolores, Director of Pharmacy Services

Date